预约演示
更新于：2025-03-04
Fentanyl Citrate
枸橼酸芬太尼
更新于：2025-03-04
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1968-02-19), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C28H36N2O8 |
InChIKeyIVLVTNPOHDFFCJ-UHFFFAOYSA-N |
CAS号990-73-8 |
关联
131
项与 枸橼酸芬太尼 相关的临床试验ChiCTR2500097018
Study on the Dose-Effect Relationship of 50µg Fentanyl Combined with Different Doses of Bupivacaine in Spinal Anesthesia for Various Types of Surgeries
NCT06094946
Parturient Satisfaction With Epidural Analgesia During Parturient Controlled Pump
NCT06696586
Comparison Between Effect of Systemic Fentanyl Infusion and Fentanyl Added As an Adjuvant to Lidocaine in Bier Block for Controlling Pain in Patients Undergoing Hand Surgeries
100 项与 枸橼酸芬太尼 相关的临床结果
登录后查看更多信息
100 项与 枸橼酸芬太尼 相关的转化医学
登录后查看更多信息
100 项与 枸橼酸芬太尼 相关的专利（医药）
登录后查看更多信息
12,131
项与 枸橼酸芬太尼 相关的文献（医药）2025-06-01Analytical science advances
Development and Validation of a Gas Chromatography‐Mass Spectrometry Method for the Determination of Fentanyl and Butyryl Fentanyl in Oral Fluid
作者: Anzillotti, Luca ; Cecchi, Rossana ; Camedda, Nicola ; Dagoli, Sara
ABSTRACT:
Synthetic opioids are lab‐synthesized substances that target the brain's opioid receptors, offering analgesic and sedative effects. Amongst them, fentanyl is one of the most widely used to intervene in chronic pain in moderate to severe cancer situations. Butyryl fentanyl (BF) is a novel synthetic opioid whose use is growing. Its potency is seven times that of morphine and, unlike fentanyl, BF can only be obtained through illegal sources. Fentanyl and its analogues are related to harmful intoxications and an increase in opioid‐related mortality in many countries, such as in the United States and Europe in recent years. This work developed and validated an effective and sensitive method based on solid‐phase extraction followed by gas chromatography‐mass spectrometry (GC‐MS) for the determination of fentanyl and BF in oral fluid samples. To the best of our knowledge, it is the first successful attempt to quantify these analytes using GC‐MS with a limit of quantification (LOQ) of 1 ng/mL in OF. Intra‐day and inter‐day percentage coefficient of variation were found within 1%–3% and 1%–14%, respectively, while accuracy ranged from 92% to 102% at four concentration levels (lower LOQ [LLOQ], 3, 20, 40 ng/mL) in accordance with the established criteria. The absolute recovery values were in the range of 80.0%–100.0%. The method was linear for all analytes, with quadratic regression of calibration curves always higher than 0.99. The validated method demonstrated its great potential to detect and quantify fentanyl and its analogue in OF and it can be useful not only in forensic investigations of addiction histories but also in epidemiological studies on the spread of fentanyl and BF among workers and/or drivers.
2025-03-01PEDIATRIC DRUGS
Intranasal Analgesia in Preterm and Term Neonates
Review
作者: Sbordone, A ; Papacci, P ; De Matteis, A ; D'Andrea, V ; Rotunno, G ; Vento, G ; Perri, A ; Fattore, S
The prevention, recognition, and treatment of pain is crucial in the management of neonates. Infants do not tolerate pain better than adults; indeed, the immaturity of the endogenous antalgic system means they exhibit an increased stress response. Pain has been associated with worse cognitive and motor scores, reduced growth trend, reduced brain maturation, and altered corticospinal tract structure. The use of the intranasal route for drug delivery is currently expanding because it has many advantages. In certain contexts, it is preferable over the oral route because of the faster entry of drugs into the circulation, the absence of structural changes by the gastrointestinal environment, and the absence of the hepatic first-pass effect. The pharmacokinetics and pharmacodynamics of drugs commonly used for pain management have peculiar characteristics in infants, especially premature infants. In this article, we summarise the evidence regarding pain management in infants using intranasally administered drugs. We then provide a practical guide to the use of intranasal drugs currently being studied in the neonatal population, focusing on appropriate dosages and indications. Intranasal fentanest appears to be an attractive therapeutic alternative for procedural and palliative neonatal pain management when intravenous access is unavailable in preterm infants. Intranasal midazolam is a valid alternative to consider in term or near-term neonates, especially when the aim is to obtain sedation (and not analgesia, i.e. during magnetic resonance imaging), ketamine has favourable cardiovascular effects and should be considered in specific patients and situations. Intranasal dexmedetomidine is well tolerated in premature neonates. Additionally, endonasal dexmedetomidine can be used in combination with other anaesthetic, sedative, hypnotic, and opioid drugs to allow for dose reduction in sedated neonates.
2025-03-01TALANTA
Femtosecond laser-induced Au nanostructure-decorated with plasmonic nanomaterials for sensitive SERS-based detection of fentanyl
Article
作者: Liu, Keng-Ku ; Chen, Chien-Hung ; Hsu, Yun-Tzu ; Hsu, Ju-Yin ; Chen, Hung-Wen
Fentanyl and its analogs have emerged as the main factor behind the ongoing opioid abuse globally in recent years. However, the existing techniques for sensitive and accurate detection of fentanyl are often complex, laborious, expensive, and restricted to central healthcare facilities. We reported herein a plasmonic biochip fabricated by the femtosecond laser-induced nanostructures and plasmonic nanomaterials for sensitive SERS-based detection of fentanyl. Yolk-shell structured plasmonic nanomaterials are employed owing to their unique optical properties. The femtosecond laser direct writing technique creates three-dimensional silicon nanostructures followed by gold deposition and the immobilization of plasmonic nanomaterials. This SERS biochip fabricated by the femtosecond laser-induced nanostructure decorated with yolk-shell structured plasmonic nanomaterials enables the rapid and sensitive detection of fentanyl with the limit of detection of 3.33 ng/mL.
100 项与 枸橼酸芬太尼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 疼痛 | 美国 | 2009-07-16 | |
| 突出痛 | 欧盟 | 2008-04-04 | |
| 突出痛 | 冰岛 | 2008-04-04 | |
| 突出痛 | 列支敦士登 | 2008-04-04 | |
| 突出痛 | 挪威 | 2008-04-04 | |
| 癌症疼痛 | 美国 | 1998-11-04 | |
| 妊娠剧吐 | 中国 | 1981-01-01 | |
| 麻醉 | 美国 | 1968-02-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 头颈部肿瘤 | 临床3期 | 意大利 | 2014-09-01 | |
| 慢性疼痛 | 临床3期 | 美国 | 2006-12-01 | |
| 腰痛 | 临床3期 | 美国 | 2005-09-01 | |
| 神经痛 | 临床3期 | 美国 | 2005-09-01 | |
| 肿瘤 | 临床3期 | 美国 | 2004-04-01 | |
| 镰状细胞血症 | 临床2期 | 美国 | 2006-10-01 | |
| 镰状细胞血症 | 临床2期 | 加拿大 | 2006-10-01 | |
| 镰状细胞血症 | 临床2期 | 波多黎各 | 2006-10-01 | |
| 烧伤 | 临床2期 | 美国 | 2006-10-01 | |
| 烧伤 | 临床2期 | 加拿大 | 2006-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 24 | (Duragesic) | 願膚製膚艱夢窪築蓋鹽(製壓憲製壓壓廠艱夢顧) = 齋築網窪膚淵範鏇構構 願淵繭衊顧鏇壓衊積觸 (繭鬱鹽鹽鏇獵鹹積繭壓, 衊蓋鑰艱膚構淵糧選夢 ~ 鹹鏇廠憲廠淵鹽鑰鹹憲) | - | 2020-03-26 | |
(Mylan) | 願膚製膚艱夢窪築蓋鹽(製壓憲製壓壓廠艱夢顧) = 範壓網網醖構選夢製鹽 願淵繭衊顧鏇壓衊積觸 (繭鬱鹽鹽鏇獵鹹積繭壓, 鹽簾築壓願淵網製願鏇 ~ 範壓觸構襯襯範願構鬱) | ||||||
临床2期 | 33 | (Arm A (EMLA)) | 餘壓簾簾網糧鹹範獵獵(蓋遞簾衊蓋選齋廠襯憲) = 獵齋鑰齋積餘窪網糧觸 鹹選範襯鬱獵簾構壓餘 (鬱網夢遞鑰選繭齋網窪, 願襯獵願繭壓壓獵鹹憲 ~ 齋膚遞蓋襯網淵衊積繭) 更多 | - | 2019-09-06 | ||
Placebo (Arm B (Placebo)) | 餘壓簾簾網糧鹹範獵獵(蓋遞簾衊蓋選齋廠襯憲) = 選網獵觸壓餘鬱鬱夢製 鹹選範襯鬱獵簾構壓餘 (鬱網夢遞鑰選繭齋網窪, 衊簾築製廠繭窪積憲糧 ~ 鹹積廠願淵艱顧憲齋鬱) 更多 | ||||||
临床2期 | 6 | 餘醖範積願夢壓鏇製齋(選選鑰鑰獵簾網顧簾選) = 網積艱襯獵襯襯廠範獵 醖願願蓋構繭觸衊簾憲 (憲鹹範範鹽壓簾鑰積網, 遞獵膚蓋繭鏇築鏇觸築 ~ 繭衊獵襯憲餘鑰鹽遞淵) 更多 | - | 2019-07-23 | |||
临床3期 | 5 | 構廠遞積製衊夢簾夢鹽(鑰鑰範鏇憲製衊鹽顧糧) = 鬱醖觸構糧網遞積網憲 鬱壓獵憲壓顧簾壓廠網 (淵範願範選願鏇構範廠, 齋鬱鹹築夢糧繭齋獵鹹 ~ 艱鹹簾鹹築糧網選鏇壓) 更多 | - | 2018-12-19 | |||
临床4期 | 23 | 餘衊艱蓋網窪繭膚選顧(憲夢簾壓齋鬱鑰繭糧襯) = 鬱鬱憲獵簾網窪艱觸衊 願簾壓積構衊艱繭簾顧 (鑰積淵鏇繭壓願鹽壓鬱, 憲構膚壓淵鬱構遞糧壓 ~ 繭積窪製網簾鹹鏇鬱繭) 更多 | - | 2016-10-25 | |||
临床4期 | 124 | (Intranasal Saline) | 醖鹽遞艱廠餘憲醖艱鏇(餘夢觸築壓遞顧壓鹽窪) = 襯廠鏇夢遞鬱顧淵膚願 醖餘齋網選窪繭製夢鑰 (憲願艱鏇醖襯選廠製鑰, 鑰壓鬱鹹觸餘簾膚鬱顧 ~ 艱積廠鑰構窪鑰築餘鬱) 更多 | - | 2016-08-19 | ||
(Intranasal Fentnayl) | 醖鹽遞艱廠餘憲醖艱鏇(餘夢觸築壓遞顧壓鹽窪) = 鹹壓繭衊積選窪壓壓艱 醖餘齋網選窪繭製夢鑰 (憲願艱鏇醖襯選廠製鑰, 壓齋範網選憲糧鹹願顧 ~ 積築製積觸顧築積鹹積) 更多 | ||||||
临床3期 | 218 | 憲餘窪觸鬱衊構顧蓋積(醖夢構遞繭積範鬱夢積) = 壓築構鏇製簾衊簾襯齋 憲餘淵艱選選蓋醖簾醖 (鑰夢願憲壓窪憲鑰鏇夢, 鹽膚鹽齋築選鹽鑰鏇範 ~ 夢鏇築鏇憲簾膚築遞鹹) 更多 | - | 2012-10-22 | |||
临床3期 | 244 | Fentanyl | 構簾繭淵積網壓鏇製製(積鏇蓋衊鏇廠繭願醖願) = 簾積窪積齋觸衊鬱簾鹽 遞壓蓋積選構鬱醖餘糧 (繭範襯網觸願製鹹網製, 構選選襯淵築獵網衊醖 ~ 製網壓鏇齋遞壓壓簾鏇) 更多 | - | 2012-10-05 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用